Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2005-01-11
2005-01-11
Scheiner, Laurie (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S007200, C435S007320, C435S007370, C435S041000, C435S252330, C424S241100, C514S054000
Reexamination Certificate
active
06841345
ABSTRACT:
The present inventors have found that certain preparations containing LPS and/or lipid A variants, derivatives, and/or analogs demonstrate non-pyrogenic properties and exhibit anti-viral activities. In particular, non-pyrogenic preparations of LPS, lipid A, LPS antagonists and lipid A antagonists, and derivatives thereof induce β chemokine secretion, such as MIP-1β, but not proinflammatory cytokines, such as TNFα, IL-1β and IL-6. Non-pyrogenic preparations of the invention have been demonstrated by the Applicant to suppress HIV replication in human peripheral blood monocytes, as described by way of example herein. The present invention provides preparations of LPS or lipid A variants, analogs and derivatives of decreased or absent pyrogenicity which can be used as therapeutics for the treatment or prevention of immunodeficiency virus infection and its consequences.
REFERENCES:
patent: 5158939 (1992-10-01), Takayama et al.
patent: 5189674 (1993-02-01), Shimizu
patent: 5191072 (1993-03-01), Hasegawa et al.
patent: 5510119 (1996-04-01), Santus et al.
patent: 5593969 (1997-01-01), Kamireddy et al.
patent: 5597573 (1997-01-01), Kamireddy et al.
patent: 5997881 (1999-12-01), Powell et al.
patent: WO 9708955 (1997-03-01), None
patent: WO9718837 (1997-05-01), None
patent: WO9523156 (1995-08-01), None
patent: WO 9116449 (1991-10-01), None
patent: WO9200101 (1992-01-01), None
patent: WO9206113 (1992-04-01), None
patent: WO9421292 (1994-09-01), None
patent: WO9725061 (1997-07-01), None
patent: WO8404526 (1984-11-01), None
patent: 0 437 016 (1991-07-01), None
patent: 0 536 969 (1993-04-01), None
patent: 0 668 289 (1995-08-01), None
patent: 2 220 211 (1990-01-01), None
patent: A-63010728 (1998-01-01), None
Cornelis, P., et al., 1992, “Stability, frequency and multiplicity of transposon insertions in the pyoverdine region in the chromosomes of different fluorescent pseudomonads”, J. Gen. Microbiol. 138:1337-1343.*
Pries, A, et al., 1992, “Identification of a lipoamide dehydrogenase gene as second locus affected in poly(3-hydroxybutryic acid)-leaky mutants ofAlcaligenes eutrophus”, FEMS Microbiol. Lett. 97:227-234.*
Öberg, B. and L. Vrang, 1990, “Screening for new agents”, Eur. J. Clin. Microbiol. Infect. Dis. 9(7):466-471.*
Yarchoan, R. and S. Broder, 1992, “Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development”, J. Enzym. Inhib. 6:99-111.*
Gait, M. and J. Karn, 1995, “Progress in anti-HIV structure-based drug design.”, TIBTECH 13(10):430-438.*
Flexner, C. and C. Hendrix, 1997, “Pharmacology of antiretroviral agents.”, inAIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition,DeVita, Jr., V., et al., eds., Lippincott-Raven Publishers, pp. 479-493.*
Pomerantz, R. J., et al., 1990, “Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression”, J. Exp. Med. 172:253-261.*
Moriuchi, H., et al., 2000, “In vitro reactivation of human immunodeficiency virus 1 from latently infected, resting CD4+T cells after bacterial stimulation”, J. Infect. Dis. 181(6):2041-4, (abstract provided).*
Verani et al., “C-C Chemokines Released by Lipopolysaccharide (LPS)-Stimulated Human Macrophages Suppress HIV-1 Infection in Both Macrophages and T-Cells”, J. of Exp. Med. 185(5):805-816 (Mar. 1997).
Baker et al., “Structural Features that Influence the Ability of Lipid A and its Analogues to Abolish Expression of Suppressor T-Cell Activity”, Infect. Immun. 60(7):2694-2701 (1992).
Clementz et al., “Function of theEscherichia colimsbB Gene, a Multicopy Suppressor of htrB Knockouts, in the Acylation of Lipid A”, J. Biol. Chem. 272:10353-10360 (1997).
Clementz et al., “Function of the htrB High Temperature Requirement Gene ofEscherichia coliin the Acylation of Lipid A”, J. Biol. Chem. 271:12095-12102 (1996).
Golenback et al., “Lipid X Protects Mice against FatalEscherichia coliInfection”, Infect. Immun. 56(4)779-784 (1988).
Karow et al., “Complex Phenotypes of Null mutations in the htr genes, whose products aare essential forEscherichia coligrowth at elevated temperatures”“Research in Microbiology” 142:289-294 (1991).
Kotani et al., “Immunobiological Activities of Synthetic Lipid A Analogues with Low Endotoxicity”, Infect. Immun. 54(3):673-682 (1986).
Lee et al., “Mutations of the htrB Locus ofHaemophilus influenzaeNontypable Strain 2019 is Associated with Modifications of Lipid A and Phosphorylation of the Lipo-oligosaccharide”, J. Bio. Chem. 270:27151-27159 (1995).
Nowotny, A., “Review of the Molecular Requirements of Endotoxic Actions”, Rev. Infect. Dis. 9(5):S503-S511 (1987).
Ogawa et al., Chemical Abstract No. 163524, “Disaccharide Derivatives as Analgesics”, vol. 1098, No. 19, Nov. 7, 1988.
Polissi et al., “Mutational analysis and properties of the msbA gene ofEscherichia coli,coding for an essential ABC family transporter”, Mol. Micro 20:1221-1233 (1996).
Pugliese, C. et al., “Relationships Between the Structure and Function of Lipopolysaccharide Chemotypes with Regard to their Effects on the Human Polymorphonuclear Neutrophil”, Molec. Immunol. 25(7):631-637 (1988).
Schnailman et al., “Genetics of lipopolysaccharide Biosynthesis in Enteric Bacteria”, Microbiol. Rev. 57:655-682 (1993).
Somerville et al., “A NovelEscherichia coliLipid A Mutant that produces an Antiinflammatory Lipopolysaccharide”, J. Clin. Invest. 97:359-365 (1996).
Sunshine et al., “Mutation of the htrB Gene in a VirulentSalmonella typhimoriumby Intergeneric Transduction: Strain Construction and Phenotype Characterization”, J. Bacteri. 179:5521-5533 (1997).
Zhou et al., “Function ofEscherichia coliMsbA, and Essential ABC Family Transporter, in Lipid A and Phospholipid Biosynthesis”, J. Biol. Chem. 273:12466-12475 (1988).
Johnson et al., “Characterization of a Nontoxic Monophosphoryl Lipid A”, Reviews of Infectious Diseases 9 (5): S512-S516 (1987).
Friedman et al., “Immunoadjuvanticity of Endotoxins and Nontoxic Derivatives for Normal and Leukemic Immunocytes”, Advances in Experimental Medicine and Biology 256:525-535 (199).
Bernstein, et al., 1991, J. Clinical invest. 88:540.
Begrasra, et al., 1992, Proc. Natl. Acad. Sci 89:6285.
Bhat et al., Glyco Biology 2:535-539 (1992).
Bunnell et al., Crit. Care Med. Suppl. 23:147 (1995).
Bunnell et al., Crit. Care Med. Suppl. 23:A151 (1995).
Chemical Abstracts, vol. 109, No. 17, Nov. 7, 1988, Abstract No. 163524, “Disaccharide Derivatives as Analgesics”.
Christ et al., J. Am. Chem. Soc. 116:3637 (1994).
Darveau et al., “Ability of Bacteria Associated With Chronic Inflammatory Disease to Stimulate E-Selectin Expression and Promote Neutrophil Adhesion”, Infect. And Immun. 63:1311-1317 (1995).
Erwin and Munford, J. Biol. Chem. 256:16444 (1990).
Fagan et al., J. Immunol. 153:5230 (1994).
Flexner, C. and C. Hendrix, 1997, “Pharmacology of antiretroviral agents,” in AIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition, DeVita, J., V., et al., eds., Lippincott-Raven Publishers, pp. 479-493.
Friedman et al., “Immunodeficiency of Endotoxins and Nontoxic Derivatives for Normal and Leukemic Immunocytes” Advances in Exp. Med. and Biol., vol. 256, (1990) pp. 525-535.
Gait, M. and J. Karn, 1995, “Progress in anti-Hiv structure-based drug design,” TIBTECH 13(10):430-438.
Golenback et al., J. Biol. Cehm. 266:19490 (1991).
International Search Report dated Mar. 17, 1999, for PCT/US98/20264, filed Sep. 28, 1998.
Johnson et al., “Characterization of a Nontoxic Monophosphoryl Lipid A,” Review of Infectious Diseases, vol. 9, No. S5 (1987) pp. S512-S516.
Karow et al., J. Bacteriol., 173:741-750 (1991).
K
Crowley Richard
Hone David M.
Lewis George
Fuierer Marianne
Hultquist Steven J.
Parkin Jeffrey S.
Scheiner Laurie
University of Maryland Biotechnology Institute
LandOfFree
Treatment and prevention of immunodeficiency virus infection... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and prevention of immunodeficiency virus infection..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and prevention of immunodeficiency virus infection... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3426252